Newton, MA · Pre-clinical biotech
Adaptilens
The first biomimetic accommodating intraocular lens - a soft lens that focuses with your eye's own muscle.
The first biomimetic accommodating intraocular lens - a soft lens that focuses with your eye's own muscle.
Somewhere outside Boston, a team of about nine people is working on a piece of plastic smaller than a shirt button. It does not look like much. It is soft, clear, and unremarkable in the hand. But the ambition packed into it is large: this lens is meant to slip into a human eye, sit where the natural lens used to be, and then - on command from the eye's own muscle - change its shape to bring the world into focus.
That is the whole pitch. An artificial lens that does not just sit there, but accommodates. Adaptilens calls it the A-IOL. The company is still pre-clinical, which is the polite biotech word for "no human has tried it yet." In April 2024 investors handed over $17.5 million to change that.
Cataract surgery is one of the most common operations on earth. A surgeon removes the eye's clouded natural lens and drops in an artificial one. It restores clarity, and it works. The trouble is what gets installed.
A standard intraocular lens has a single fixed power. It can be tuned for distance, or for reading, but not both. So patients trade a cataract for a pair of reading glasses. The premium alternatives - multifocal, trifocal, extended-depth-of-focus lenses - split incoming light to cover several distances at once. The catch is the side effects: halos around headlights, glare at night, a softening of contrast that nobody mentions in the brochure.
The young, healthy lens does none of this. It is flexible. When you look from a distant horizon to a book in your lap, a ring of muscle around the lens flexes, the lens changes shape, and your focus follows. That trick fades with age, and surgery has never bothered to bring it back. Adaptilens exists because someone refused to accept that as the end of the story.
Dr. Liane Clamen took an unusually long run-up. She studied English at Harvard before going back for her MD there, then trained in ophthalmology at Massachusetts Eye and Ear. The idea started in the late 1990s, when she was researching the history of intraocular lenses and noticed something missing: nobody had built an artificial lens that behaved like a real, young one.
The thought refused to leave. It incubated from roughly 2002 onward, through residency, through the daily evidence of patients who could see clearly again but still reached for their glasses to read a menu. The bet was simple to state and very hard to execute - do not improve the fixed lens, replace the whole idea of it. Build a lens that imitates biology instead of working around it.
A patent for the accommodating lens was granted in 2019, and the company was founded the same year. To turn the concept into something injectable and durable, Clamen partnered with Professor Matthew Becker at Duke University, whose lab developed "bottlebrush" polymers - molecules shaped, more or less, like the brush you clean a bottle with - tuned to the exact optical and mechanical properties an eye demands.
Note the gap between "good idea" and "funded company": roughly two decades. Patience is a medical-device prerequisite, not a virtue.
The A-IOL is designed to do what your 20-year-old lens did automatically.
Soft and flexible like a natural lens, not a rigid fixed-power disc. The goal is to copy biology rather than engineer around it.
The lens reacts to the eye's natural focusing signal from the ciliary muscle, shifting shape for near, intermediate, and distance vision.
Designed to skip the halos, glare, and reduced contrast that come with splitting light across multifocal and trifocal lenses.
For the record: the lens is still in development and is not approved for investigational or commercial use. Everything here is a plan, not a product on a shelf.
The case for Adaptilens is partly demographic. People are living longer, and the lens of the eye keeps clouding on schedule. The National Eye Institute projects the U.S. cataract population will climb from about 24 million today toward 50 million by 2050. Every one of those people will need a lens. The only open question is which kind.
A chart that essentially draws itself. The hard part was never the demand - it was building a lens worth that demand.
The money came from people who do this professionally. The Series A was led by Perceptive Xontogeny Venture Funds, with Pillar VC, 380 Cap, and Accanto Partners joining - several of them returning from the seed round. Validation arrived earlier, too: MassChallenge's medical-devices cohort gave the company an early stamp of approval, a crash course in FDA strategy, and a direct line to its first investors.
Most vision companies promise an upgrade. Adaptilens is promising a rewind. The point is not to out-engineer the multifocal lens at its own light-splitting game; it is to stop splitting light at all and hand the focusing job back to the eye, the way it used to work before age took it away.
That framing explains the company's odd shape - small team, long timeline, deep academic roots, a founder who waited twenty years for the materials science to catch up to the idea. This is not a move-fast business. It is a get-it-right business, because the customer is your eye and there is no patch release for an implanted lens.
Return to that small clear object on the bench in Newton. Today it is a prototype, a patent, and a pile of polymer chemistry. It has never been inside a person. The next milestone - first-in-human trials - is the one that turns a very good idea into evidence, and the $17.5 million exists mostly to get there.
If it works, the math is hard to ignore: tens of millions of aging eyes, each one a candidate for a lens that focuses on its own. If it does not, it joins a long list of elegant ideas that biology declined to cooperate with. Adaptilens is betting it lands on the first side of that line - and it has spent twenty years getting ready to find out.
A lens that remembers how to focus. The only thing left to convince is a human eye.